| Prev Close | 44.79 |
| Day Low/High | 43.74 / 45.43 |
| 52 Wk Low/High | 20.10 / 300.00 |
| Avg Volume | 1.64M |
Tilray Inc. (TLRY)
43.88
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 80.56M |
| Market Cap | 4.35B |
| EPS | -0.80 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
2 Big Earnings Reports I'll Be Watching This Week
A huge week is coming up for these well-known stocks.
Cause for Caution? Top Executives Selling Tilray Stock
It might not be time to panic yet about Tilray, but there's likely a problem ahead.
With Tilray, You Won't Win Any Valuation Arguments
Short interest is back in the low single digits while Tilray still enjoys one of the smallest floats for a cannabis company.
Tilray Touts Global Ambition as Erosion of Canadian Market Expected
A key aspect of the international expansion is the company's recent acquisition of hemp-food producer Manitoba Harvest in February.
Tilray Is Not My Favorite Canadian Cannabis Stock
Apparently, this game is all about growth right now. It certainly is not about margins.
Kass: Tilray Is Promising but I Prefer This Other Stock in the Pot Space
Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.
Tilray Has Rebased and Looks Poised to Rally Again - Consider Buying Strength
Let's check out the charts and indicators for this so-called pot play.
Stock of the Day - Tilray
Pot stocks like Tilray have very ambitious valuations but the potential upside (in mergers and, fundamentally in food, drink, supplemental and medical applications) are undeniably immense. The view of a possible rapid rise in revenues and profits (a...
Tilray Stock Lights Up as Partnerships Obscure Profitability Problem
The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.
3 Important Earnings Reports I'll Be Watching This Week
This quarter is a heavy test for Tilray because of the stock's lofty valuation.
Chart of the Day: Vetting the Value of Cannabis Companies
Assessing Aurora and its peers, strictly on the numbers.
Aurora Cannabis' Is a Beast but the Stock Has Entered a Tricky Area Now
Aurora Cannabis' hiring of deal maker Nelson Peltz opens up a wealth of new possibilities for the Canadian pot company.
Jim Cramer: Buy Aurora Cannabis Because Nelson Peltz Knows What Can Go Right
I know that Nelson is fascinated by the medicinal properties chiefly as a replacement for opioids, the scourge of this country.
Aurora Cannabis Could Triple in the Months Ahead
The price of ACB is moving up today and a fresh look at the charts and indicators seems like a good idea.
Melius Research Launches Cannabis Industry Coverage
In its first report on cannabis companies, Melius says prices are high.
Acreage Wants to Be Your All-American Cannabis Company
In an industry where Canadian companies have been grabbing the headlines, New York-based Acreage Holdings has methodically built itself into the largest American cannabis firm.
Short-Selling Is Really Hard. Just Ask Citron Research
Examining the influential short-sellers' big winners and losers provides important insights into trading and investing.
S&P 500 Is Testing Resistance, and How to Play Activision: Market Recon
China trade discussions will continue to be a key driver in Wednesday's market action.
Pot Stocks Fade as Momentum Cools
There are some big shifts Wednesday in names that have recently been the hottest.
Cannabis Stocks Are Getting Their Second Wind
Let's check out the charts of four big names in the space.
Excuse Me, Would You Like Some Cannabis With Your Coffee?
CBD could make coffee an around the clock craze.
Chart of the Day, Part 2: A Closer Look at Constellation's Big Cannabis Bet
Canopy Growth's smoking engine won't necessarily ensure smooth sailing for Constellation.
Not Up In Smoke (Part Deux)
"One last thing." -- Lt. Columbo I have recently been focused on Canopy Growth Corp. CGC as an interesting speculation in 2019 (I have been adding over the last few days). In fact, I commented today on the stock. After the close, Tilray was upgraded...
Real Money Goes Behind the Scenes of the Budding Cannabis Industry
In the interest of due diligence, we went and took a close look at the ground floor of the newest investment craze.